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AbstrAct
Introduction: The EQ-5D allows the achievement of two essential components of any measure of health-related quality of life to be 
used in cost-utility economic evaluations: (i) a profile describing the health status in terms of domains or dimensions; and (ii) a numeric 
value associated with the health status described.
Aim: The Portuguese version of the EQ-5D questionnaire was completed in 1998, based on guidelines set by the EuroQol Group, in-
cluding translation and back translation procedures. Despite its wide use in Portugal, until now it had not yet been published studies that 
initially led to the Portuguese version and the guarantee of acceptability, reliability and validity. The purpose of this article is to document 
these first values relating to the Portuguese version of the EQ-5D. 
Material and Methods: We used three different samples: a first one with 1,500 individuals representative of the Portuguese population; 
a second with 140 individuals just intended for the reliability test; and a third sample with 643 individual patients with cataracts, asthma, 
chronic obstructive pulmonary disease, or rheumatoid arthritis.
results: The acceptability was assessed by the number of missing responses. It was also found a marked ceiling effect, with a large 
part of the sample not reporting any problems in the dimensions of the EQ-5D.
Discussion: The construct validity was tested by examining the degree to which low values of EQ-5D were positively associated with 
increasing age, being female, and the sick, as well as the values of dimensions of the SF-36v2 scale. Convergent validity was based on 
correlations between EQ-5D values and other specific measures. The EQ-5D showed moderate to high correlations with other disease-
specific measures of health status and health related quality of life. 
conclusion: We can state that the Portuguese version of the EQ-5D has a good accessibility, reliability and validity in measuring 
health.
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rEsUMO
Introdução: O EQ-5D permite a junção de duas componentes essenciais de qualquer medida de qualidade de vida relacionada com a 
saúde a ser usada em avaliações económicas de custo-utilidade: (i) um perfil descrevendo o estado de saúde em termos de domínios 
ou dimensões; e (ii) um valor numérico associado ao estado de saúde anteriormente descrito.
Objectivo: A versão portuguesa do questionário EQ-5D foi finalizada em 1998, com base em normas de orientação definidas pelo 
Grupo EuroQol, incluindo os procedimentos de tradução e retroversão. Apesar da sua larga utilização em Portugal, até agora ainda 
não tinham sido publicados os estudos que conduziram inicialmente à versão portuguesa e à garantia de aceitabilidade, fiabilidade 
e validade. O propósito do presente artigo é, assim, documentar estes primeiros valores referentes à versão portuguesa do EQ-5D. 
Material e Métodos: Foram utilizadas três amostras diferentes: uma primeira com 1 500 indivíduos representativa da população 
portuguesa; uma segunda com 140 indivíduos apenas destinada ao teste da fiabilidade; e uma terceira amostra com 643 indivíduos 
doentes com cataratas, asma, doença pulmonar obstrutiva crónica ou artrite reumatoide.
resultados: A aceitabilidade foi avaliada pelo número de respostas em falta. Foi também encontrado um marcado efeito de teto com 
grande parte da amostra a não reportar quaisquer problemas nas dimensões do EQ-5D. 
Discussão: A validade de construção foi testada pela análise do grau com que valores baixos de EQ-5D estavam positivamente as-
sociados ao aumento da idade, ao ser do sexo feminino, e ao estar doente, assim como a valores de dimensões da escala SF-36v2. 
A validade convergente foi baseada nas correlações entre valores do EQ-5D e outras escalas específicas de condição de saúde. O 
EQ-5D apresentou correlações moderadas a altas com outras medidas de estado de saúde e de qualidade de vida relacionada com 
a saúde, específicas de cada doença.
conclusão: A versão portuguesa do EQ-5D tem uma boa aceitabilidade, fiabilidade e validade na medição do estado de saúde.
Palavras-chave: Estado de Saúde; Portugal; Qualidade de Vida; Medição de Saúde; Questionários.
INtrODUctION
Framework
 The EQ-5D is a generic tool for use as a measure 
health outcome (QdVRS) allowing for the calculation of a 
single index value for health status. It was developed by 
the EuroQoL group in 19871, became public in 1990;2 and is 
based on a health-related classification system of life states 
consisting of five dimensions: mobility, self-care, usual 
activities, pain/discomfort and anxiety/depression. Each 
of these dimensions has three associated severity levels, 
accounting for the absence of health problems (level 1), some 
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problems (level 2) and extreme problems (level 3), lived or 
perceived by the respondent. Therefore, this system allows 
for the establishment of 35 = 243 different health states.
 The main reason for the initial development of 
this measuring instrument was the fact that existing 
questionnaires such as the SF-36 and the NHP did not 
allow for the calculation of a generic index representing an 
assigned value (according to preference intensity) given to 
a health status, that could be used in cost-utility economic 
assessments. As such, the EuroQoL group filled a need to 
build a generic health index intended for use in economic 
assessments. They also projected a measuring instrument 
that would complete the remaining measures and allow for 
reference data collection in multinational comparisons.
 According to the authors, the descriptive system was 
obtained over three phases. These included a first revision 
of the existing major health status generic measuring 
instruments, an analysis showing the result of the experience 
of the members of the group in using these instruments and 
the evidence obtained in face-to-face interviews.1 Apart 
from completing this descriptive system, the respondent is 
asked to record the valuation of his own health status using 
a visual analogue scale from 0 (worst imaginable health 
state) to 100 (best imaginable health state), commonly 
called the EQ-VAS thermometer.
 The EQ-5D has been designed as a self-completion 
measuring instrument. The respondent description of 
the health status, obtained using a classification system, 
includes five dimension scales with values of 1 to 3, and a 
rating scale, the EQ-VAS, which are the components most 
commonly used by researchers and healthcare professionals 
only interested in obtaining information on the impact of 
health status on life and quality of life. Nevertheless, the 
responses to this descriptive system may also be aggregated 
using an algorithm sensible to the society values, i.e., to the 
values commonly associated by individuals to each health 
status, thereby producing a value index.
Descriptive system of EQ-5D
 Table 1 presents the dimensions and the levels of the 
descriptive system of EQ-5D.
 For each individual, the result of this description is 
presented using a five digit number. Therefore, for example, 
a 21132 health status represents a health status of a 
person with some problems in mobility, without problems 
in both self-care and in the pursuit of his usual activities 
but with intense pain/discomfort and moderately anxious or 
depressed.
 Beyond this description and in order to ensure a first 
approach to health gains, especially when it is a first 
assessment, the EQ-5D also allows the respondent to give 
a perception of his health status, by comparison with his 
general level of health in the previous 12 months. In this 
comparison, the respondent is asked to choose between 
the response options “better”, “the same” or “worse”.
the value associated to the health status
 The EQ-5D involves two ways of associating a value to a 
person’s own health status. The first one, which completes 
the health status description, allows the respondent to 
place his own health status in a visual analogue scale, 
as presented in figure 1. Using the direct measurement 
technique,3 the respondent is asked to draw a line between 
the “box” representing his own health state in that moment, 
Table 1 – EQ-5D descriptive system.
Dimension Level
Mobility
(1) I have no problems in walking about
(2) I have some problems in walking about
(3) I am confined to bed
self-care
(1) I have no problems with self-care
(2) I have some problems in washing and dressing myself
(3) I am unable to wash and dress myself
Usual activities
(1) I have no problems in performing my usual activities
(2) I have some problems in performing my usual activities
(3) I am unable to perform my usual activities
Pain/discomfort
(1) I have no pain or discomfort
(2) I have moderate pain or discomfort
(3) I have extreme pain or discomfort
Anxiety/depression
(1) I am not anxious or depressed
(2) I am moderately anxious or depressed
(3) I am extremely anxious or depressed
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and the EQ-VAS rating scale thermometer from 0 to 100, 
considering 0 as the worst health state imaginable and 100 
as the best health state imaginable (Fig.1).
 Nevertheless, it should be noted, that this visual 
analogue scale, despite being a simple process to give 
a value, does not allow for the representation of the 
commitment between quantity and quality of life4 and, for 
that reason, it does not yield cardinal values or utilities and 
as such cannot contribute towards QALY (quality-adjusted 
life years) assessment.
 The second way of associating a value with a specific 
health state, upon its description and classification, is to 
obtain a value based on the collected preferences of general 
population. This value lies in a scale of 1 (perfect health) to 
0 (death) yet admitting negative valuations corresponding 
to health states considered worse than death.
 The first approach to determine this preference value 
was developed by Dolan et al.5,6 based in an initial set of 45 
health states and 2.997 members of the British population, 
selected in a study called MVH (Measurement and Value of 
Health) carried out by  York University.7
 Through the application of generalized linear least-
squares regression method, these researchers found an 
additive function allowing for the conversion a five digit 
number into a cardinal index which varies between -0.59 and 
1.00, adapted to the British reality.5 This index is sensitive to 
the severity level of each dimension and includes a constant 
term α for any health state different from 11111 and a N3 
term identifying a more severe level of any dimension. That 
is, the additive function is defined by
 V = 1 – α – MO – CP – AH – DM – AD – N3
in which 1 represents a value of perfect health used 
to rescale the final result in the interval of 0 to 1, α is a 
constant value which represents the non-coincidence of the 
value of any dimension related to the level 1, N3 is another 
constant which represents the presence of the level 3 in 
any dimension and the variables MO, CP, AH, DM and AD 
assume the values given by the first five lines in Table 2 for 
the level of each of the five dimensions.
 For example, for the health state 21132 referred above, 
we find an index value obtained as follows:
V = 1 – 0.081 – 0.069 – 0.000 – 0.000 – 0.386 – 0.071 – 0.269 = 0.124
 It is possible to obtain a QALY value associated to this 
health state, with an index obtained in this manner,8 i.e., it 
allows for a measurement of healthcare benefit, that may be 
used in economic assessments.
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Figure 1 – EQ-VAS rating scale (thermometer).
Table 2 – EQ-5D descriptive system.5
Dimension Level 1 Level 2 Level 3
(MO) Mobility
(sc) self-care
(UA) Ususal activities
(PD) Pain/discomfort
(AD) Ansiety/depression
0.000
0.000
0.000
0.000
0.000
0.069
0.104
0.036
0.123
0.071
0.314
0.214
0.094
0.386
0.236
 α
 N3
 0.081
 0.269
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 Several European and non-European countries use 
valuation systems adapted to their own country and/or 
standards for the EQ-5D.4,9-13 In Portugal, , the Health Studies 
and Research Centre of the University of Coimbra (Centro 
de Estudos e Investigação em Saúde da Universidade de 
Coimbra (CEISUC)) with the financial support of the ACS 
(Alto Comissariado para a Saúde) and Pfizer Laboratories 
led a major health measurement and valuation pro-ject 
using EQ-5D, with the first publications already avai-lable 
online.14,15 Divided in two parts (valuation and standards), 
its objectives were (1) to validate the EQ-5D for the 
Portuguese reality, (2) to determine a valuation system for 
Portugal adapted to the cultural Portuguese reality and (3) 
to measure the QdVRS of the Portuguese population and 
therefore, to determine the Portuguese standards for EQ-
5D.
 The purpose of this study is to document the first 
valuations regarding the Portuguese EQ-5D version. At 
first, the creation process of the Portuguese EQ-5D version 
will be described, followed by its semantic and linguistic 
equivalence, upon which some aspects regarding its 
validation will be analysed.
MAtErIAL AND MEtHODs
Data
 For this paper, we collected data mainly from three 
samples: 
 In the first sample, data was collected by a specifically 
recruited market research company, using telephone 
interviews and a randomized sample, stratified by NUTS II, 
gender and age, of 1,500 individuals from the Portuguese 
po-pulation aged 18 or more and living in all regions of 
Portugal (18 districts of Portuguese mainland, Azores 
and Madeira). The researchers had only access to the 
anonymous data. 
 The 150 records in the second sample were also 
collected by the same market research company and each 
participant was contacted by phone one week later. In this 
sample, although the company interviewers obviously knew 
the identity of the people they were again interviewing, that 
information was never included in the database nor was 
revealed to the researchers.
 The third sample included 643 patients in four groups 
of pathology: 352 had cataracts, 115 had asthma, 72 had 
chronic obstructive pulmonary disease (COPD) and 104 
had rheumatoid arthritis (RA). The patients with asthma and 
DPOC were consecutively recruited by chest physicians 
during slightly more than one year.16 Patients with cataracts 
were selected from a waiting list for surgery in two public 
hospitals17 and patients with RA were recorded in a 
database from the Portuguese Rheumatic Diseases League 
(Liga Portuguesa de Combate às Doenças Reumáticas 
(LPCDR)) and were referred by rheumatologists.18
 All these samples had patient’s explicit and informed 
consent, as well as Ethics Committee approval. Patients 
unable to complete the questionnaire, due to some pathology 
or due to illiteracy were helped by nursing professionals.
statistical analysis
 Acceptability. In order to test this property, we intended 
to verify the feasibility of the EQ-5D and to what extent it 
is well accepted by the respondents. Based on the three 
samples, the response rates and the rates of fully completed 
instruments were determined. We assumed the following 
hypothesis:
 H1: The individuals do not present major problems when 
filling the EQ-5D, as reflected by a low rate of missing data;
 H2: The EQ-VAS, as slightly more complex than the 
descriptive system, is associated with a higher percentage 
of missing data.
 Distribution. Data from the three samples enabled the 
analysis of response distribution. We also intended to identify 
the presence of a ceiling effect, i.e., a great percentage of 
respondents recording high valuations for health states. 
Therefore, we assumed the following hypothesis:
 H3: The EQ-5D descriptive part presents a ceiling effect.
 Reliability. As the EQ-5D is mainly used for economic 
assessment studies and health policies and not in clinical 
practice, was tested at an aggregated level. Test-retest 
reliability was assessed in sample 2, in which each 
respondent was questioned twice in a two-week period. 
We used for this purpose the Cohen’s kappa coefficient 
calculator as well as the criteria defined by Landis and 
Koch.19 In addition, internal consistency was measured 
using Cronbach’s alpha coefficient and using established 
qualification criteria.20
 Construct validity. In order to test this type of validity, 
we analysed the existing correlations between the EQ-5D 
scores in sample 1 and, in sample 3, in specific health 
states. Both samples also allowed correlation between the 
valuations obtained through EQ-5D or EQ-VAS with the 
socio-demographic variables or with valuations of the SF-
36v2, an instrument that allows for the measurement of eight 
main health dimensions, all of them using seve-ral items 
and scored on a 0 to 100 scale. In the latter, extreme values 
correspond to the worst and the best possible HRQOL 
respectively. The measured dimensions included physical 
functioning (PF), role-physical (RP) role-emotional (RE), 
bodily pain magnitude (BP), general health (GH), vitality 
(VT), social functioning (SF) and mental health (MH).21-24
 The following four hypotheses for EQ-5D and four more 
for EQ-VAS were tested: 
 H4: Respondents pointing out problems on any 
dimension of the 
EQ-5D will present lower valuations on all dimensions 
scales of the SF-36v2;
 H5: Respondents referred with EQ-5D anxiety/
depression problems will present larger reductions on the 
SF and MH SF-36v2 dimensions;
 H6: Respondents with pain/discomfort problems will also 
describe lower valuations on SF-36v2 BP dimension;
 H7: Elder respondents of those referring some disease 
present worse valuations of health state dimensions;
 H8: The EQ-VAS valuations will be higher in respondents 
describing a best health in the self-valuation SF-36v2 scale;
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 H9: The EQ-VAS valuations correlate negatively with 
aging;
 H10: Respondents who describe the presence of a 
disease present lower EQ-VAS valuations;
 H11: Women describe lower EQ-VAS valuations then 
men.
 These hypotheses were tested using chi-square, t-Student, 
Mann-Whitney and Kruskall-Walis tests and Spearman 
correlation coefficient. We used the Scheffé post-hoc 
method for multiple comparisons adjustment. On the 
other hand, we tested multiple regression models to assess 
the relationship between the EQ-5D and the valuations 
obtained by the specific health state instruments. In order 
to test the discriminant validity we assessed how functional 
disability measured by SF-36v2 would be discriminated by 
the three response levels of each dimension.
 Criteria validity. As there is no gold standard for HRQOL, 
the criteria validity was tested by comparing with the utility 
valuations obtained by SF-6D in sample and with the data 
obtained in sample 3 collected in patients with a pathology 
and at the same time who have given specific measures of 
their pathology. 
 The SF-6D is another index based in preferences, 
obtained upon conversion of 11 items for SF-36 in a 
classification system with six dimensions, each one with four 
to six levels, allowing for the overall description of 18.000 
different health states.25,26 The SF-6D descriptive system 
includes the following dimensions: physical functioning, role 
participation, social functioning, bodily pain, mental health 
and vitality.
 Therefore, for the subsamples relating to cataracts, 
asthma, COPD and rheumatoid arthritis, beyond EQ-5D 
and SF-6D, the Portuguese versions of Catquest, Asthma 
Quality of Life Questionnaire (AQLQ(S)), Asthma Control 
Questionnaire (ACQ), Clinical COPD Questionnaire (CCQ) 
and Arthritis Impact Measurement Scales 2 (AIMS2-SF) 
were used. 
 Catquest has been designed with the purpose of 
analysing cataract surgery results, not only regarding visual 
acuity, but also regarding the impact of surgery on daily 
activities, visual constraints, symptoms associated with 
cataracts and patient’s level of independence.27,28 
 AQLQ is a specific questionnaire for patients with 
asthma, with questions regarding four domains (symptoms, 
activity constraints, emotional functioning and environmental 
exposure). AQLQ(S) is a standardized version of AQLQ29,30 
in which the five questions regarding the activity domain are 
generic and relate to the five more commonly chosen by 
patients in AQLQ original version. 
 ACQ is a small questionnaire including seven items 
and also developed by Juniper et al.31 with the purpose of 
measuring the asthma control. Five of these items concern 
symptoms and activity constraints, one pertaining to the 
estimated FEV1 percentage and another to the use of 
short-acting bronchodilators.
 CCQ is a small clinical questionnaire measuring COPD 
breathing difficulties, obtaining information regarding 
symptom severity, related constraints and the effect of 
therapy.32 It is available in several languages and in two 
versions: one with a weekly periodicity and another one 
covering a 24-hour period, which may be used as a diary. 
It includes ten items, divided in three domains: symptoms, 
functional state and mental state. 
 Finally, the AIMS2-SF is a specific health quality specific 
instrument for patients with rheumatoid arthritis, initially 
developed by Meenan et al.33 and subject to several 
updates.34 It allows for the measurement of five components 
of health quality: physical, symptoms, affect, social 
interaction and role.
 This form of convergent validity has been tested using 
the following hypotheses and using Spearman and Pearson 
correlation coefficients:
 H12: Correlation between EQ-5D/VAS and SF-6D;
 H13: Correlation between EQ-5D/VAS and Catquest;
 H14: Correlation between EQ-5D/VAS and AQLQ;
 H15: Correlation between EQ-5D/VAS and ACQ;
 H16: Correlation between EQ-5D/VAS and CCQ.
 H17: Correlation between EQ-5D/VAS and AIMS2-SF.
 Data were analysed with IBM SPSS Statistics, version 
20. For every statistical analysis, a maximum significance 
level of 0.05 was adopted.
rEsULts
semantic and linguistic adaptation
 EQ-5D Portuguese version has been created in 1997 by 
CEISUC followed by the translation classical process.35-37 
Later on, in a harmonisation process between the versions 
in Latin based languages, some aspects requiring 
adaptation have emerged. That was the case of the third 
level of response to the question about mobility. Initially, 
the sentence ‘I am confined to bed’ was translated by ‘Eu 
estou acamado(a)’ which may be considered as too harsh, 
regarding the intensity planned by the authors in the original 
version. It has been decided to change to ‘Tenho de estar 
na cama’.
 In the options of response to the dimension ‘usual 
activities’ the authors of the original version have questioned 
whether the verb ‘desempenhar’ should be changed by the 
verb ‘realizar’ in order to be better understood by Portuguese 
respondents. It was considered as more correct to keep the 
Portuguese initial proposal, despite the verb used in the 
Spanish version.
 The third aspect concerned the dimension ‘pain/
discomfort’ and the use of the adjective ‘moderados’ and 
‘extremos’ at the end of the sentences in order to assure 
they were related with pain, as well as with discomfort. 
This was a translation option which has been immediately 
changed.
 In the introductory sentences to the analogue visual 
scale the word ‘quão’ was initially used. This was the case 
of the sentences ‘Para ajudar as pessoas a classificarem 
quão bom ou mau é o seu estado de saúde hoje’ and 
‘Gostaríamos que indicasse nesta escala quão bom 
ou mau é, na sua opinião, o seu estado de saúde hoje’. 
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In the harmonisation process, it was decided that this 
word, although existing in Portuguese, it is not commonly 
used and could create problems of understanding to some 
respondents. Therefore, these sentences have been 
updated without using this word 
 It has been submitted in 1998 as the Portuguese version 
of the EQ-5D, from this review, which since then has been 
used in Portugal, and made available, upon request, by the 
CEISUC.
sample
 Social-demographic data of the respondents in the three 
samples are represented on Table 3.
 We found in all samples a slight predominance of 
female subjects, married or non-married couples. Sample 3 
presents, as expectable given these pathologies involved, 
an older population, with a lower education level, pensioners 
living alone or with the partner.
Acceptability and distribution
 The distribution of the five dimensions in each sample, 
for the EQ-5D and EQ-VAS is shown in Table 4.
 In the three samples, 2,293 respondents completed 
the EQ-5D questionnaire, without any missing data in the 
three first dimensions, 1 (0.1%) missing data in the pain/ 
discomfort dimension and 7 (0.5%) missing data in the 
anxiety/depression dimension, what confirms the H1 
hypothesis. No difficulties were encountered as regards the 
understanding of the questionnaire. As regards EQ-VAS, 
only 25 respondents (1.7%) did not answer this question on 
sample 1, 5 (3.3%) on sample 2 and 52 (8.1%) on sample 
3, confirming the H2 hypothesis.
 Between the five EQ-5D dimensions, the proportion of 
having any problem was higher for pain/discomfort and for 
anxiety/depression. EQ-VAS average was 74.9 for samples 
1 and 2 and 58.6 for sample 3 with unhealthy respondents. 
Whenever the H3 hypothesis was confirmed, we found a 
ceiling effect, i.e., few respondents were placed on level 3 
for the five dimensions. In fact, on samples 1 and 2, the 
mobility, self-care and usual activities dimensions, always 
presented valuations above 83% on level 1 (no constraint). 
In addition, in the pain/discomfort and anxiety/depression 
dimensions, more than half of the respondents selected 
level 1. A similar situation occurred on sample 3, in which 
Table 3 – Social-demographic and clinical data distribution.
Variable Values
sample 1 sample 2 sample 3
N % N % N %
size 1 500 100.0 150 100.0 643 100.0
Gender Female
Male
789
711
52.6
47.4
78
72
52.0
48.0
377
265
58.7
41.3
Age
18 – 29 years
30 – 49 years
50 – 69 years
70 or + years
Minimum
Maximum
Mean
Standard deviation
346
494
388
272
18
91
48.0
18.8
23.1
32.9
25.9
18.1
39
44
50
17
18
85
46.4
17.7
26.0
29.3
33.3
11.3
12
100
206
320
18
92
64.9
15.5
1.9
15.7
32.3
50.2
Family situation
Single 
Married or cohabiting
Divorced or separated
Widow
375
894
100
123
25.2
59.9
6.7
8.2
41
91
9
8
27.5
61.1
6.0
5.4
52
419
40
132
8.1
65.2
6.2
20.5
Educational level
≤ 6 years
7-12 years
> 12 years
469
682
337
31.5
45.8
22.6
39
69
41
26.2
46.3
27.5
469
111
63
72.9
17.3
9.8
Occupational status
Employed
Unemployed
Retired or pensioner
Student
Domestic work
Other
725
176
380
127
83
1
48.6
11.7
25.5
8.5
5.6
0.1
60
29
39
14
7
1
40.0
19.3
26.0
9.3
4.7
0.7
179
15
416
0
31
0
27.9
2.3
64.9
0.0
4.8
0.0
Household 1 to 2 elements
3 or + elements
642
840
43.3
56.7
61
89
40.7
59.3
587
56
91.3
8.7
Pathology Yes
No
594
894
39.9
60.1
58
91
38.9
61.1
643
0
100.0
0.0
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cut-points were obviously lower, in 62% and 40%, 
respectively, yet still very high. A more detailed analysis 
of subsamples by pathology, in sample 3, allowed us to 
observe that this ceiling effect was even more evident than 
initially observed (Table 5).
 The mode of the distributions of dimensions related with 
mobility, self-care and usual activities is represented on 
the first level, meaning a strong ceiling effect for cataracts, 
asthma and COPD, as expected for elderly patients with 
a restrictive disease in what concerns usual activities. The 
same applies to the pain/discomfort and anxiety/depression 
dimensions in the patients with asthma and COPD, as with 
the self-care dimensions in patients with RA. As regards 
pain/discomfort and anxiety/depression dimensions in 
Table 4 – Distribution of the responses to EQ-5D and ERQ-VAS dimensions in the three samples.
EQ-5D
sample 1 sample 2 sample 3
N % N % N %
Mobility
No problems
Moderate problems
Extreme problems
1 249
244
7
83.3
16.3
0.5
129
21
0
86.0
14.0
0.0
405
238
0
63.0
37.0
0.0
self-care
No problems
Moderate problems
Extreme problems
1 428
66
6
95.2
4.4
0.4
145
5
0
96.7
3.3
0.0
561
73
9
87.2
11.4
1.4
Usual activities
No problems
Moderate problems
Extreme problems
1 255
209
36
83.7
13.9
2.4
125
23
2
83.3
15.3
1.3
402
235
6
62.5
36.5
0.9
Pain/discomfort
No problems
Moderate problems
Extreme problems
830
599
70
55.4
40.0
4.7
80
66
4
53.3
44.0
2.7
256
350
37
39.8
54.4
5.8
Anxiety/depression
No problems
Moderate problems
Extreme problems
980
449
64
65.6
30.1
4.3
102
43
5
68.0
28.7
3.3
283
330
30
44.0
51.3
4.7
EQ-VAs
Percentile 5
Percentile 10
Percentile 25
Percentile 50
Percentile 75
Percentile 90
Percentile 95
Minimum
Maximum
Mean
Standard deviation
34.8
50.0
60.0
80.0
90.0
99.0
100.0
0.0
100.0
74.9
21.2
40.0
50.0
60.0
80.0
90.0
100.0
100.0
5.0
100.0
74.9
20.3
30.0
37.0
50.0
59.0
70.0
80.8
90.0
20.0
100.0
58.6
17.0
Table 5 – Distribution of EQ-5D dimensions in the subsamples per pathology.
EQ-5D Dimension
cataracts15 
(n = 352)
Asthma14 
(n = 115)
cOPD36 
(n = 72)
rA16 
(n = 104)
N % N % N % N %
Mobility
No problems
Moderate problems
Extreme problems
220
132
0
62.5
37.5
0.0
82
33
0
71.3
28.7
0.0
55
17
0
76.4
23.6
0.0
48
56
0
46.2
53.8
0.0
self-care
No problems
Moderate problems
Extreme problems
316
32
4
89.1
9.1
1.1
109
6
0
94.8
5.2
0.0
68
3
1
94.4
4.2
1.4
68
32
4
65.4
30.8
3.8
Usual activities
No problems
Moderate problems
Extreme problems
220
128
4
62.5
36.4
1.1
87
28
0
75.7
24.3
0.0
55
15
2
76.4
20.8
2.8
40
64
0
38.5
61.5
0.0
Pain/discomfort
No problems
Moderate problems
Extreme problems
108
216
28
30.7
61.4
8.0
76
38
1
66.1
33.0
0.9
56
16
0
77.8
22.2
0.0
16
80
8
15.4
76.9
7.7
Anxiety/depression
No problems
Moderate problems
Extreme problems
136
192
24
38.6
54.5
6.8
71
43
1
61.7
37.4
0.9
52
19
1
72.2
26.4
1.4
24
76
4
23.1
73.1
3.8
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patients with cataracts and in the remaining four dimensions 
in patients with RA, mode is situated at the second level. 
 
reliability
 Table 6 presents three indices that demonstrate the 
reliability of this measuring instrument: percentage 
agreement, Spearman correlation coefficient and Cohen 
kappa coefficient.
 The values obtained indicate very good correlation 
values and moderate (self-care and pain/discomfort) to 
good kappa values (remaining dimensions).
 The value of Cronbach alpha coefficient for EQ-5D was 
0.716, which signifies an acceptable internal coherence. 
In addition, Intraclass Correlation Coefficient (ICC) for 
EQ-VAS between the two periods was high (0.862 with a 
confidence interval of 0.808 to 0.901), as well as the 
Pearson correlation coefficient (0.768; p < 0.001).
construct validity
 In order to answer the question regarding construct 
validity, relating EQ-5D with SF-36v2 dimensions, as well 
as the three first hypotheses referred above, the values 
for each level without/with problems on each of the EQ-5D 
dimensions, the median value of the several SF-36v2 
dimensions’ scores, as well as the statistical significance 
indicator are presented in Table 7.
 Our findings are in agreement with hypothesis H4. as 
the distributions of respondents that reported moderate 
or extreme problems in each EQ-5D dimension always 
presented a significantly lower median than those that did 
not describe any problems, as already described.38 Also, in 
the anxiety/depression dimension, the differences regarding 
median of values for SF-36v2 MH dimension (32.0 points) 
and SF (25.0 points) are higher than the difference for PF 
(15.0 points), in agreement with hypothesis H5 and already 
observed.39 The difference in points for the median of the 
SF-36v2 PR dimension, between those referring in EQ-5D 
that do not have any pain and those referring problems 
regarding pain is of 39.0 points (hypotheses H6), also 
previously demonstrated.40
 In order to answer hypothesis H7, the relationship 
between responses to EQ-5D dimensions, age and the 
presence of pathology are presented in Table 8. 
 As illustrated, the elderly and the most severely ill 
patients are those who significantly reported more problems 
in all EQ-5D dimensions.
 Table 9 present the average values of EQ-VAS for each 
of the levels of variables, allowing for testing hypotheses H8 
to H11.
 EQ-VAS was initially analysed as regards self-evaluation 
of the health state (question 1 of SF-36v2) and the age 
group. As  shown in this table, EQ-VAS is strongly related 
Table 6 – EQ-5D reliability.
EQ-5D Dimension concordance (%) correlation (α) cohen’s kappa
Mobility
self-care
Usual activities
Pain/discomfort
Anxiety/depression
91.9
97.3
89.3
77.3
85.0
0.677
0.586
0.661
0.633
0.661
0.647
0.586
0.308
0.555
0.633
Table 7 – SF-36v2 median for each EQ-5D dimension.
EQ-5D Dimension N PF rP bP HG rE Vt sF MH
Mobility
 No problem
 Problem 
1 249
251
**
95.0
45.0
**
93.7
50.0
**
74.0
51.0
**
62.0
44.4
**
91.7
58.3
**
70.0
45.0
**
87.5
62.5
**
80.0
56.0
self-care
 No problem
 Problem
1 428
72
**
90.0
25.0
**
93.7
31.3
**
72.0
31.0
**
62.0
40.0
**
91.7
41.7
**
70.0
35.0
**
87.5
50.0
**
80.0
52.0
Usual activities
 No problem
 Problem
1 255
245
**
95.0
45.0
**
93.7
50.0
**
72.0
42.0
**
62.0
40.0
**
91.7
58.3
**
70.0
40.0
**
87.5
62.5
**
84.0
55.0
Pain/discomfort
 No problem
 Problem
830
669
**
95.0
75.0
**
100.0
68.7
**
100.0
61.0
**
67.0
50.0
**
100.0
75.0
**
75.0
50.0
**
100.0
75.0
**
84.0
68.0
Anxiety/depression
 No problem
 Problem
980
513
**
95.0
80.0
**
100.0
75.0
**
74.0
62.0
**
65.0
50.0
**
100.0
66.7
**
71.7
50.0
**
100.0
75.0
**
88.0
56.0
PF – Physical functioning. RP – Role-physical. BP – Bodily pain magnitude. GH – General health. RE – Role-emotional. VT – Vitality. SF – Social functioning. MH - Mental health. 
** p < 0.001
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with health self-evaluation, as the difference between the 
average on each health level is significant (p < 0.001, 
except for the rise between levels ‘ótima’ and ‘muito boa’), 
confirming hypothesis H8, also reported by other authors.
41,42 
 In addition (hypothesis H9), EQ-VAS was observed to 
decrease significantly with increasing age (p < 0.001 for all 
age groups, except between 18-29 and 30-49 age groups, 
in which p < 0.01), confirming previous findings.42,43
 Respondents with some disease also presented worst 
global evaluations of their health than healthy respondents 
(hypothesis H10), and the same occurred with female vs. 
men (hypothesis H11).
criterion validity
 In order to test this type of validity, we compared the 
valuations collected by EQ-5D, initially with those obtained 
by SF-6D and subsequently with those obtained with specific 
measuring instruments. These results are presented in 
Table 10.
 In what concerns the comparison between measuring 
instruments based in preferences (hypothesis H12) and 
although these are measured with different descriptive 
systems, we compared the results for EQ-5D and EQ-VAS 
with SF-6D dimensions. We found moderate correlations, in 
line with other studies.44-46
 Regarding the subsample of Patients with cataracts, 
we compared the EQ-5D indexes with the Catquest areas 
(hypothesis H13). We demonstrated, as expected, the 
pre-sence of moderate and inverse correlations between 
utility measurement and the level of Activity, symptoms 
for cataracts and  general opinion about Catquest.17 We 
highlight the presence of another moderate and inverse 
correlation between EQ-VAS and disability, what could be 
interpreted to mean that an improvement in one of these 
areas may lead to a rise in the patient’s health state utility 
and therefore to an improvement in HRQOL. 
 With the analysis of consistency between EQ-5D and 
the results of asthma specific instruments, we observed 
that AQLQ(S) domains and their global valuations are 
directly and moderately/strongly correlated with the utility 
measures (hypothesis H14), which could be interpreted as 
improvement in some of these areas increasing utility. On the 
other hand, we observe the presence of strong and inverse 
correlations between the ACQ global valuation and the 
EQ-5D measures (hypothesis H15).
 In what concerns COPD, EQ-VAS seemed to be 
correlated with all CCQ dimensions and the descriptive part 
of the EQ-5D presented a good correlation with the global 
value (hypothesis H16).
 Finally, with the analysis of the results of the application 
of the specific measuring instrument of life quality in 
Patients with RA, we demonstrated the presence of strong 
and inverse correlations between the utility measures 
Table 8 – Relationship between EQ-5D responses. Age group and pathology, N (%).
EQ-5D dimentions with problems
Variable Mobility self-care Usual activities Pain/discomfort Anxiety/depression
Age
 < 65 years
	 ≥	65	years
**
115 (10.3%)
134 (36.7%)
**
38 (3.4%)
33 (9.0%)
**
121 (10.8%)
121 (33.2%)
**
409 (36.5%)
250 (68.7%)
**
361 (32.3%)
146 (40.6%)
Pathology
 No
 Yes
**
63 (7.0%)
185 (31.1%)
**
11 (1.2%)
61 (10.3%)
**
50 (5.6%)
192 (32.3%)
**
273 (30.5%)
385 (64.9%)
**
225 (25.3%)
282 (47.6%)
** p < 0.001
Table 9 – Relationship between EQ-VAS, health self-assessment and context variables.
Variable Level N Mean standard variation
Mean comparison
F sig.
Health self-valuation
Excellent
Very good
Good
Reasonable
Weak
216
319
391
451
98
88.3
87.7
78.8
63.0
42.7
14.8
9.7
14.9
18.5
28.9
241.9 **
Age
18 – 29 years
30 – 49 years
50 – 69 years
70 or more years
345
493
383
254
84.3
79.8
68.5
62.2
14.2
18.3
22.2
23.6
86.2 **
Pathology No
Yes
887
578
80.8
65.9
17.7
22.8
197.1 **
Gender Female
Male
768
707
72.9
77.1
23.2
18.5
15.1 **
** p < 0.001
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and symptom-associated dimensions, affect and social 
interaction of the AIMS2-SF (hypothesis H17). 
cONcLUsIONs 
 Health results measures are becoming more and more 
essential for monitoring clinical practice, especially when 
gain associated to different therapies is considered to be 
marginal. One of the instruments used to measure these 
health results is the EQ-5D. It is applicable to a large set of 
health states and therapies, and not only does it set a health 
profile, but also it sets an index which expresses HRQOL of 
the respondents. 
 The results obtained using the EQ-5D may be used 
for planning and allocating resources in health sector, 
at national and at regional level and also by pathology, 
allowing as well for integration in the Health National Plan, 
as already practiced in other countries. Therefore, there is a 
clear practical application of the results by health authorities, 
national and/or regional.
 The utility values of health states of the Portuguese 
population may also be used in economic assessments 
of health technology, for drug economic assessment, as 
well as different health programs (when choosing between 
different alternatives, the one that allows reaching the 
health state with higher utility should be preferred). 
Nevertheless, any measuring instrument, before its 
implementation, needs acceptable properties. We can 
assume, with this study, the following general conclusions 
regarding the Portuguese version of the EQ-5D:
 □ The translation and cultural adaptation have been 
made based on the best practice held in scientific terms;
 □ It presented a great acceptability of the respondents, 
with few missing data and presence of the expected ceiling 
effect;
 □ The test-re-test reliability has been confirmed and 
considered high and the internal coherence has been 
considered as acceptable;
 □ The construct validity has been checked through 
confirmation of previously defined hypotheses.
 □ The criterion validity has been successfully tested 
through the behaviour analysis with the EQ-5D and EQ-VAS 
in relation to another instrument based on preferences (the 
Table 10 – Correlation between SF-6D and EQ-5D.
Measuring instrument Dimensions EQ-5D EQ-VAs
sF-6D
Physical functioning
Role-physical
Social functioning
Pain magnitude
Mental health
Vitality
 -0.520**
 -0.412**
 -0.419**
 -0.509**
 -0.480**
-0.442**
 -0.486**
 -0.449**
 -0.428**
 -0.607**
 -0.541**
 -0.411**
catquest
Disability
Cataract symptoms
Activity level
General opinion
Car driving
-0.07
-0.13*
-0.29***
-0.29***
 0.10   
-0.20**
-0.31***
-0.23***
-0.33***
 0.08
AQLQ(s)
Activity limitations
Symptoms
Emotional function
Environmental stimuli
Global evaluation
 0.50***
 0.56***
 0.33***
 0.31***
 0.53***
 0.55***
 0.53***
 0.35***
 0.37***
 0.55***
AcQ Global evaluation -0.51*** -0.51***
ccQ
Symptoms
Functional status
Mental status
Global evaluation
-0.278*
-0.527**
-0.059
-0.358**
-0.362**
-0.523**
-0.304**
-0.540**
AIMs2-sF
Physical dimension
Symptoms
Affect
Social interaction
Performance
-0.01
-0.93**
-0.40**
-0.41**
-0.05
 0.07
-0.76**
-0.29
-0.59**
 0.14
* p < 0.05   ** p < 0.01   *** p < 0.001
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SF-6D). The latter instrument, although generic for health 
measuring, was utilized with specific instrument dimensions 
for cataracts, asthma, COPD and RA.
 Thus, we can say that the Portuguese version of the 
EQ-5D has a good acceptability and validity in health state 
measuring.
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